Canopy Immuno-Therapeutics
June 16, 2025
Company Presentation
Immunology
Canopy is an emerging biotech redefining autoimmune therapeutics through its groundbreaking Antigen-Drug Conjugate (AgDC) platform. Backed by leading US-based VCs, the company is led by Dr. Kfir Oved, a serial bio-entrepreneur, alongside Chairman Cedric Francois (NASDAQ:APLS) and board member and investor John Cox (NASDAQ:DYNE).
AgDCs utilize two distinct MoAs to precisely target both autoreactive antibodies and pathological B-cell clones, sparing 99.9% of protective immunity. This innovative, non-immunosuppressive approach holds the potential to deliver long-term remission or even a cure, positioning AgDCs as potentially first-line therapy for antibody-mediated autoimmune diseases.
Canopy is on track to initiate a Phase 1 trial for AChR+ MG in H1/26. Backed by robust IP including 14 patents across 8 patent families, the company’s pipeline covers Graves’ disease/Thyroid Eye Disease (TED), Pemphigus Vulgaris, Membranous Nephropathy, Immune Thrombocytopenic Purpura (ITP), and MuSK MG.
Company HQ City:
Megadim
Company HQ State:
Israel
Company HQ Country:
Israel
Year Founded:
2020
Lead Product in Development:
MGAC-007 - AChR+MG
GRVC-007 - Graves' Disease / TED
PVC-002 - Pemphigus Vulgaris (PV)
CEO
Dr. Kfir Oved
Year Founded
2020
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
NA
When you expect your next catalyst update?
Clinical data
What is your next catalyst (value inflection) update?
18 months
Website
https://canopy-biotech.com/
Primary Speaker
)
)
)
)
){kind=logo}
)
){kind=logo}
)
){kind=logo}